Q-omics provides the consensus-scored FBXO43 profile across patient tissues and cancer cell-line models. FBXO43 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FBXO43 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, FBXO43 RNA expression shows 19,526 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where FBXO43 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO43 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO43 survival associations across molecular data types. FBXO43 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO43 RNA expression–survival associations across cancer types. High FBXO43 expression shows unfavorable associations in ACC, KIRP, KIRC, KICH, LIHC and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FBXO43 RNA expression.
This table summarizes FBXO43 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FBXO43. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO43 shows higher tumor expression in KIRC, LUAD, HNSC, LIHC, UCEC and STAD. The KIRC box plot shows higher FBXO43 RNA expression in tumor versus normal tissue (log2 FC = +0.326, t-test p < 0.001).
This table shows molecular features associated with FBXO43 in patient tissues and cancer cell lines. In patient samples, FBXO43 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO43 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
